Rowasa patents expiration

ROWASA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7645801 MYLAN SPECIALITY LP Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Jul, 2027

(3 years from now)

Rowasa is owned by Mylan Speciality Lp.

Rowasa contains Mesalamine.

Rowasa has a total of 1 drug patent out of which 0 drug patents have expired.

Rowasa was authorised for market use on 24 December, 1987.

Rowasa is available in enema;rectal dosage forms.

The generics of Rowasa are possible to be released after 24 July, 2027.

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 24 December, 1987

Treatment: NA


More Information on Dosage

ROWASA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic